{
    "medicine_id": "c5605f4734836f186dd93b0b757c31f2e8065d4e",
    "platform_id": "DB11134",
    "metadata": {
        "name": "Active FE 400 mcg Capsule",
        "composition": "400 mcg Cupric oxide",
        "clinical_particulars": {
            "therapeutic_indications": "No FDA or EMA approved therapeutic indications",
            "contraindications": {
                "disease": "Copper toxicity involves gastrointestinal irritation and liver and kidney toxicity Reported No Observed Adverse Effect Levels NOAELs of copper are in the range of 23 104 mg kg bw day but kidney effects have been shown in male rats at levels as low as 10 mg kg bw day L2437 Severe intoxication is associated with serum copper levels greater than 500 mcg dL The estimated lethal dose in an untreated adult is 10 to 20 g copper L2422",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "For pharmacodynamic information of copper refer to drug entry for DB09130 Copper II oxide nanoparticles are known to generate reactive oxygen species ROS leading to cytotoxicity A32656 In a comparative toxicity assay nanoparticles caused significant mitochondrial depolarization leading to DNA damage A32656 In the human skin organ culture study topical application of copper oxide CuO nanoparticles induced inflammatory cytokine secretion and necrosis _in vitro_ indicating that the nanoparticles may adhere to the skin surface and react with the local acidic environment A32657",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}